ARAGEN capping out-of-pocket costs for Medicare beneficiaries. Downward price pressures effectively pass costs onto manufacturers, who have to look for cost-cutting and cost optimization as a remedy. Outsourcing is the most optimal and feasible way to do exactly this, and India is positioned well by falling outside pending friendshoring limitations while maintaining a relatively low overall manufacturing cost. “Outsourcing today has become a “must have” rather than a “good to have” strategy in the life sciences sector. Its not just about cost-cutting, but also ready access to an immense talent pool of scientists and an ecosystem that delivers world class pharmaceuticals to the world. Aragen with its nearly 25 year history of delivering CRO/CDMO services to customers with its 4000+ staff is uniquely positioned to take advantage of this trend”. Another trend that came up in the discussion was the waves various companies are making in the biologics space. For instance, we discussed that while a link between amyloid plaques and Alzheimer’s disease is believed to exist, companies’ understanding of what causes what —i.e., are amyloid plaques a precursor to Alzheimer’s, or an early symptom?— is still limited. Consequently, companies are making a “big bet” when designing and implementing longitudinal studies concerning one theory or another, which incentivizes outsourcing relationships that can greatly assist in the CRO process. “Aragen integrates the capabilities of a CDMO with the research depth of a CRO, creating a seamless, flexible model for advancing complex drug development projects. This approach enables us to provide agile, end-to-end support across drug development, making it a valuable partner for personalized medicine solutions.” GRANT PLAYTER Editor 24/7 BIOPHARMA The world can’t wait for what begins at BIO — let’s create something impactful together! BOOK YOUR MEETING NOW! Write to: info@247biopharma.com
RkJQdWJsaXNoZXIy MjY2OTA4MA==